CLOs on the Move

Zucara Therapeutics

www.zucara.ca

 
Zucara Therapeutics, a CDRD and MaRS Innovation portfolio company, is developing the first drug therapy to prevent hypoglycemia in people with diabetes. Our first-in-class therapeutic is focused on improving glucagon counterregulation by inhibiting somatostatin which is dysregulated in Type 1 diabetes.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.zucara.ca
  • 4th Floor 2405 Wesbrook Mall
    Vancouver, BC CAN V6T 1Z3
  • Phone: N/A

Executives

Name Title Contact Details

Similar Companies

Imago BioSciences

Imago BioSciences is translating true scientific insights into transformative treatments allowing patients to live longer, disease-free lives.

Gamma Bio

Enabling the Promise of Advanced Therapies

Cryofab

Cryofab is a Kenilworth, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gene Logic

Gene Logic is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bionano Genomics

At Bionano Genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. Our team is not afraid to venture into uncharted territory to look for answers. We welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. Our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what`s missing from sequencing-based data. Saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. At Bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality of life for all.